Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease ; volume:19 ; number:1 ; day:27 ; month:12 ; year:2024 ; pages:1-14 ; date:12.2024
Orphanet journal of rare diseases ; 19, Heft 1 (27.12.2024), 1-14, 12.2024
- Creator
-
Lenders, Malte
Nowak, Albina
Cybulla, Markus
Kaufeld, Jessica
Köhn, Anja Friederike
Muschol, Nicole Maria
Kurschat, Christine
Brand, Eva
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-024-03503-4
- URN
-
urn:nbn:de:101:1-2503052139213.602774306932
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lenders, Malte
- Nowak, Albina
- Cybulla, Markus
- Kaufeld, Jessica
- Köhn, Anja Friederike
- Muschol, Nicole Maria
- Kurschat, Christine
- Brand, Eva
- SpringerLink (Online service)
Other Objects (12)
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
Detailed characterization of anti-drug antibodies against enzyme replacement therapy in Fabry disease
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
01.04 Non Invasive Evaluation of Arterial Remodeling in Patients with Fabry Disease after Enzyme Replacement Therapy
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
Detailed characterization of anti-drug antibodies against enzyme replacement therapy in Fabry disease
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
01.04 Non Invasive Evaluation of Arterial Remodeling in Patients with Fabry Disease after Enzyme Replacement Therapy
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
Detailed characterization of anti-drug antibodies against enzyme replacement therapy in Fabry disease
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
01.04 Non Invasive Evaluation of Arterial Remodeling in Patients with Fabry Disease after Enzyme Replacement Therapy